Study finds few COVID-19 patients get rebound symptoms after Paxlovid treatment

Mayo Clinic researchers studied the outcomes of 483 high-risk patients treated for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, together marketed as Paxlovid. Only a handful developed COVID-19 rebound symptoms, and the researchers say more studies are needed to determine why.

source https://medicalxpress.com/news/2022-06-covid-patients-rebound-symptoms-paxlovid.html